That is an entirely different ball game. Zeiss should have launched the neurosurgical product and OIL will be struggling to keep up with demand. Viewnvivo will be taking the MK market and some and Peter Delaney
"will continue to investigate opportunities for Optiscan." Peter has always wanted to get back into Gastro and he has all the contacts so we might see OIL back there, women`s heath is another area I`m sure will be looked at and maybe revisit robotics. There is also the possibility based on the success of the Neuro product that Zeiss will expand into ENT and spinal. With that in mind I would give a range of 30c - 50c (conservative) depending on what additional applications/prospects are in place in 12 mths!!
Ann: Appendix 4D and Financial Statements - 31 Dec 2016, page-13
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.005(3.23%) |
Mkt cap ! $129.4M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 14.0¢ | $71.49K | 479.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 6886 | 1 |
View Market Depth
| Last trade - 12.32pm 04/12/2024 (20 minute delay) ? |
| OIL (ASX) Chart |
